Author

Laura T. Gray

University of ChicagoORCID 0000-0002-5958-4405Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Aaron T. AlpariD· 1 shared Abigail L. LauterbachiD· 1 shared Ani SolankiiD· 1 shared Anna J. SlezakiD· 1 shared David E. GerberiD· 1 shared Esra A. AkbayiD· 1 shared Hemanta BaruahiD· 1 shared Jeffrey A. HubbelliD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Aaron T. AlparORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologyJournal for ImmunoTherapy of CancerPeer-reviewedJan 1, 2025

A novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models

Ryan R Kowash, Manoj Kumar Sabnani, Laura T. Gray…·Esra A. Akbay

This paper develops a novel MICA/B-targeting antibody that enhances NK cell activity and shows therapeutic efficacy in KRAS LKB1 mutant lung cancer models.

8 citations

mouseexperimental assay

𝕏 PostBluesky

BioengineeringbioRxivPreprintMar 21, 2024

Engineered Flt3L Drives Tolerogenic State to Attenuate Anti-drug Antibody Responses

Aaron T. Alpar, Rachel P. Wallace, Kirsten C. Refvik…·Jeffrey A. Hubbell

The paper describes a method using engineered Flt3L to induce a tolerogenic immune state, reducing anti-drug antibodies to a fungal enzyme.

DOI 10.1101/2024.03.21.586168

humanproteomics

𝕏 PostBluesky